MASITINIB FOR TREATMENT OF SEVERELY SYMPTOMATIC INDOLENT SYSTEMIC MASTOCYTOSIS: ADDITIONAL EFFICACY ANALYSES FROM THE RANDOMIZED, PLACEBOCONTROLLED, PHASE 3 STUDY
The New England Journal of Medicine May 2017
18/05/2017 –
KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma